ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 2,910,000 shares, a decline of 16.4% from the February 29th total of 3,480,000 shares. Approximately 10.7% of the shares of the stock […]
ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price […]
ALX Oncology (NASDAQ:ALXO) Trading Down 3 6% themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway,
By Dean Seal One of ALX Oncology's board members has taken over as chief executive as founder Jaume Pons transitions into a new role as chief scientific.